NIH GUIDE, Volume 22, Number 33, September 17, 1993




National Institute of Allergy and Infectious Diseases

The Developmental Therapeutics Branch, Basic Research and Development

Program, Division of AIDS, National Institute of Allergy and

Infectious Diseases (NIAID), has a requirement for the directed

acquisition and evaluation of potential tuberculosis antimicrobials.

The Request for Proposals (RFP) will contain two parts, with separate

work statements for each part.  Part A is the directed acquisition,

distribution, and database component of this effort and Part B is the

evaluation component.  In Part A, the contractor will acquire

compounds for screening against M. tuberculosis, maintain a

computerized inventory for tracking of compounds, and coordinate and

distribute compounds for evaluation (to the Contractor for Part B).

Part B will require the evaluation and screening of compounds with

potential as anti-tuberculosis agents.  In Part B, the contractor

will evaluate and screen compounds for antimicrobial activity against

M. tuberculosis, evaluate the potential of selected compounds to

inhibit the replication of intracellular M. tuberculosis, and develop

and utilize new assays.

Offerors may respond to more than one Part, but must submit separate

Technical and Business proposals for each (under separate cover) to

be considered.  In order to avoid any potential conflict of interest

by the acquisition contractor (Part A), a mandatory qualification

criterion will be included to exclude pharmaceutical or chemical

companies from participating as offerors.  A pharmaceutical or

chemical company is defined as an organization that sells drugs

and/or chemicals to the general public for profit.  An organization

with any such commercial activity shall be excluded from competition.

Also, approaches to Part B using a "virulent" form of M. tuberculosis

must have a Bio-Safety Level 3 Facility at time of award to qualify.

This announcement is a new solicitation and it is anticipated that

there will be one award for each Part.  The issuance of the RFA will

be on or about September 17, 1993, and proposals will be due by COB

on or about December 17, 1993.  One cost-reimbursement, five-year

contract is anticipated for each Part.


A short-form version of the RFA will be available, for informational

purposes, which includes only the background information, the full

Statement of Work, and Evaluation Criteria.  There is sufficient

information in this document to enable prospective offerors to

determine if they have the expertise/capability to meet the

Government's requirements.  A full-text version will also be

available, which includes all the necessary information, business

forms, etc., in order to submit a proposal.  There are a limited

number of full-text versions available.  Therefore, request the short

form RFP first, then the full-text version only if you are going to

submit a proposal.  All requests must be in writing.  Specify whether

you are requesting the short-version or the full-text version of the

RFP.  FAX requests are acceptable, but it is preferred that requests

be made in writing and two self-addressed mailing labels be provided.

Requests for the RFA may be directed to:

Mr. Ross Kelley

Contract Management Branch

National Institute of Allergy and Infectious Diseases

Solar Building, Room 3C07

6003 Executive Boulevard

Bethesda, MD  20892

Telephone:  (301) 496-2509

FAX:  (301) 402-0972


Return to 1993 Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.